Bracebridge Capital LLC’s TriSalus Life Sciences Warrant TLSIW Stock Holding History

Bracebridge Capital LLC’s Portfolio TLSIW Stock Details TLSIW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-92,880	Closed	-$151K	–	43
2024 Q2	$151K	Hold	92,880	–	–	0.03%	16
2024 Q1	$92.9K	Sell	92,880 -5,977	-6%	-$5.97K	0.01%	19
2023 Q4	$118K	Hold	98,857	–	–	0.03%	15
2023 Q3	$37.6K	Hold	98,857	–	–	0.01%	20
2023 Q2	$4.14K	Hold	98,857	–	–	﹤0.01%	46
2023 Q1	$6.07K	Hold	98,857	–	–	﹤0.01%	60
2022 Q4	$7.41K	Hold	98,857	–	–	﹤0.01%	78
2022 Q3	$6K	Hold	98,857	–	–	﹤0.01%	101
2022 Q2	$8K	Hold	98,857	–	–	﹤0.01%	102
2022 Q1	$25K	Buy	+98,857	New	+$42.5K	﹤0.01%	102

Other funds holding TLSIW

Vestcor Inc Fredericton, New Brunswick, Canada $4.05B AUM 34.56% 1-Year Est. Return

Foster Victor Wealth Advisors Greenville, South Carolina $2.02B AUM 20.94% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Alpha Capital Management Austin, Texas $770M AUM 23.14% 1-Year Est. Return

Cowen and Company New York $2.97B AUM 105.25% 1-Year Est. Return

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Bracebridge Capital LLC's TLSIW Position: Q3 2024 in Review

Bracebridge Capital LLC sold out of TriSalus Life Sciences Warrant (TLSIW) in Q3 2024, closing a stake of 92,880 shares — an estimated $151K sold.

Bracebridge Capital LLC first reported a position in TLSIW in Q1 2022 and held it in 10 quarters. The position peaked at $151K in Q2 2024. 8 funds tracked by Wall St. Rank hold TLSIW as of Q3 2024.

Bracebridge Capital LLC reported no remaining TriSalus Life Sciences Warrant position as of Q3 2024 after selling out during the quarter.
Bracebridge Capital LLC sold 92,880 TriSalus Life Sciences Warrant shares in Q3 2024, an estimated $151K.
Bracebridge Capital LLC first reported a position in TriSalus Life Sciences Warrant in Q1 2022 and held it in 10 quarters.
Bracebridge Capital LLC's TriSalus Life Sciences Warrant position peaked at $151K in Q2 2024.
8 funds tracked by Wall St. Rank held TriSalus Life Sciences Warrant as of Q3 2024.

Based on Bracebridge Capital LLC's 13F filing for Q3 2024, filed 14 Nov 2024.